Infusion Pump Market Size, Share and Industry Analysis 2030
The global Infusion Pump market size was estimated at USD 12 billion in 2021 and is expected to surpass around USD 24.6 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 8.3% during the forecast period 2022 to 2030.
Key Takeaways:
Infusion pumps like implantable pumps, insulin pumps and ambulatory chemotherapy pumps, help manage a variety of diseases, including diabetes and cancer, in home care settings. Ambulatory infusion pumps are wearable or portable while infusion pumps help in the precise delivery of fluids like medicines, antibiotics and nutrients in the body under a controlled environment. These are commonly deployed in ambulatory surgery centers, hospitals, infusion clinics, long-term care facilities, and home settings. Over the years, the preference for home healthcare has risen, thanks to the surging cases and prominence of chronic disorders. Surge in healthcare spending, especially with respect to hospitalization favor the worldwide industry as well. Home healthcare offer an affordable option to the patients, especially in comparison to expensive hospital care. This helps bring down the expenditure in terms of healthcare services. With the heightened need to cut down the rate of hospital stays; more and more patients are using ambulatory infusion pumps that are affordable compared to other types of infusion pumps and are easier to use too.
Since infusion pumps help administer vital fluids, which include high-risk medications, any error while using these devices can lead to serious harm to the patient. It can even cause death. This can be a key challenge given the negative impact on the product demand.
Emerging nations like India, Brazil and China will present significant opportunities to the global firms in the infusion pumps industry. These countries have diversified healthcare sectors, with the rising cases of chronic and infectious disorders, along with surging number of R&D of advanced medical technologies. Other than this, infrastructural advances in healthcare facilities, and the low-cost production advantage in Asia Pacific can prompt more players to invest in this region over the following years.
Report Scope of the Infusion Pump Market
|
Report Coverage |
Details |
|
Market Size |
US$ 24.6 Billion by 2030 |
|
Growth Rate |
CAGR of 8.3% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
By Product, By Application, By End User and Region, |
|
Companies Mentioned |
Becton, Dickinson and Company (US), Baxter International (US), B. Braun (Germany), ICU Medical (US), Fresenius Kabi (Germany), Smiths Medical (US), Medtronic PLC (Ireland), Moog Inc. (US), Avanos Medical, Inc. (US), Nipro Corporation (Japan), Terumo Corporation (Japan), Insulet Corporation (US), Ypsomed Holding AG (Switzerland), Tandem Diabetes Care (US), JMS Co., Ltd. (Japan), Micrel Medical Devices SA (Greece), InfuTronix Solutions LLC (US), Zyno Medical LLC (US), Roche Diagnostics (Switzerland), Teleflex, Inc. (US), Mindray Medical International Limited (China), Epic Medical (Singapore), SOOIL Development Co., Ltd. (South Korea), Shenzhen MedRena Biotech Co., Ltd. (China), and CODAN Medizinische Geräte GmbH & Co KG (Germany). |
Infusion Pump Market Dynamics
Driver: Growing number of surgical procedures performed
Over the years, there has been a significant rise in the number of surgical procedures performed across the globe. This can be attributed to the rising geriatric population and the growing prevalence of obesity and other lifestyle diseases. Obesity is one of the key causes of ardiovascular and orthopedic diseases.The risk of coronary heart disease, joint and tissue damage, cancer (of the breast, colon, rostate,endometrium, kidney, and gallbladder), ischemic stroke, and type 2 diabetes mellitus also increases with obesity. Infusion pumps play a critical role in the continuous and controlled medication administration during and after different types of surgeries.
Chemotherapy, gastroenterology, analgesia/pain management, and diabetes are the key application areas of infusion pumps. Infusion pumps are also widely used for the local administration of narcotic analgesics and anesthetics following bariatric surgery, cardiothoracic surgery, and laparoscopic cholecystectomy. With an increase in the number of surgeries performed, the demand for infusion therapy is expected to increase.
Restraint: Stringent regulatory requirements for new products
Infusion pumps are designed to deliver liquid medication and other solutions to a patient’s body and are subject to rigorous standards and requirements to protect the health and safety of patients. The infusion pumps market is regulated by various regulatory authorities such as the US Food and Drug Administration (FDA), the Medicines and Healthcare Products Regulatory Agency (MHRA), and the European Medicines Agency (EMA) for the approval of new products. In European countries, the CE mark certification is necessary to legally market and sell infusion pumps. Infusion pumps (non-implantable) are classified as Class II b devices, and implantable infusion pumps are Active Implantable Medical Devices (AIMD). There are almost 300 UK-specific standards for medical devices. The current process for developing new infusion pumps across several geographies is time-consuming and expensive. This is likely to hamper the growth of the infusion pump market during the forecast period.
Opportunity: Growing adoption of specialty infusion systems
The adoption of several specialty infusion pumps is on the rise globally. Patient-controlled analgesia (PCA) pumps, enteral pumps, insulin pumps, and implantable infusion pumps are the different types of specialty infusion pumps available in the market. PCA pumps induce anesthesia in a controlled manner and reduce the complications associated with anesthetics. These pumps are also widely used for pain management during labor pain and chronic diseases. Enteral infusion pumps are imperative medical tools for patients who face difficulties caused by indigestion due to recent surgeries or functional inabilities of various digestive organs. The increasing incidence of preterm births, the shift from parenteral to enteral nutrition, and the rising prevalence of chronic diseases have increased the adoption of enteral infusion pumps.
Challenge: Increasing incidence of medication errors and lack of wireless connectivity in most hospitals
Medication errors are the most significant causes of medical injuries, representing 19.4% of all adverse events. Intravenous (IV) infusions have been identified as frequent contributors to medication errors. A multihospital study published in BMJ Quality & Safety in 2016 found that 60% of IV infusions had at least one error associated with their administration. General infusion pumps are designed to improve the accuracy and continuity of IV infusions by allowing nurses to program an hourly rate and volume. However, studies highlight that these devices are involved in 35% to 60% of the estimated 770,000 adverse drug events (ADEs) that occur each year. Most ADEs associated with IV infusion devices occur because of nurses manually inputting incorrect settings into the pump. The most common infusion errors include unit errors, multiple of ten errors, miscalculations, and push-button mistakes. Fatal errors occur due to decimal entry errors while programming infusion pumps (for instance, programming morphine at 90 ml/hr instead of 9,0 ml/hr, causing a tenfold overdose.
Volumetric infusion pumps held the largest market share of 17.8% in 2021. The high share of these pumps was due to them being capable of delivering continuous and very specific amounts of fluids at very slow to very fast rates. Based on product, the intravenous infusion pump market is segmented into volumetric infusion pumps, syringe infusion pumps, insulin infusion pumps, enteral infusion pumps, ambulatory infusion pumps, patient-controlled analgesia infusion pumps, and implantable infusion pumps.
The ambulatory infusion pumps, which are used to deliver liquid nutrients and medications to a patient in both emergency situations and for chronic conditions, contributed to a significant market share in 2021, as they are widely favored for the delivery of nutrients and medications.
The availability of other pumps like patient-controlled analgesia (PCA) pumps, insulin pumps, and smart pumps will contribute to the supplementary growth of this segment. The rising demand for enteral and syringe pumps is contributing to the burgeoning preference for the Intravenous Infusion pump which will also lead to segment growth.
Lately, smart pumps with controlled IV medication and error-prevention software are widely used as these pumps are equipped with advanced features like drug libraries, which help in storing the amount of the medicated fluid given to the patient, and its barcode technology, which helps in the verification of a patient’s identity and also helps prevent drug administration errors.
On the other hand, insulin infusion pumps are anticipated to register the highest CAGR over the forecast period. This is due to the fact that the global burden of diabetes and related complications has surged in the last decade mainly due to changing lifestyles and urbanization. This pump segment is expected to flourish in the latter future as it has a low incidence of infections and a low incidence of delivery system failure during treatment.
Application Insights
The pediatrics /neonatology segment held the largest market share of 27.5% in 2021. Based on disease indication, the market has been segmented into chemotherapy diabetes, gastroenterology, analgesia/pain management, pediatrics/neonatology, haematology, and others. Pediatrics/Neonatology held the largest market share in 2021 owing to the fact that the treatment for pediatrics has advanced considerably and with the rising number of births globally the demand for effective pediatric care has also surged
This indicates that the segment uses intravenous infusion pumps predominantly for their medical procedures requiring the delivery of fluids at a customizable and precise programmed rate.
On the other hand, the haematology segment is estimated to advance significantly during the forecast period. With the rising incidences of surgeries and blood cancer (hemophilia), the demand for intravenous infusion pumps has seen a surge in hematology for treatments like blood transfusion, which is expected to increase in coming years.
Intravenous pumps are used for hematology as it is the only way that blood can be transfused into a patient’s body in a precise, compact, continuous manner. Moreover, the flow can be controlled manually or can be automated, avoiding the risk of failure during the treatment.
End User Insights
Hospitals are supposed to overwhelm the worldwide market. As a result of rising emergency clinic confirmations around the world. The market is separated into emergency clinics, wandering consideration settings, specialty facilities, and home consideration settings in view of the end clients.
The clinics section represented the biggest portion of the market in 2021 because of emergency clinics' high buying force of the most costly mixture gadgets, huge patient pool visiting these offices, and status of prepared staff to work the pump. In any case, the home consideration settings fragment is supposed to develop at the quickest compound annual growth rate during the conjecture time frame because of expanded reception of mobile pumps and an inclination for site of care the board to diminish cost trouble.
The Asia Pacific market is expected to witness a significant CAGR of 8.7% during the forecast period. The regional countries are population-dense, with elevating burden of chronic diseases like diabetes, cardiovascular and cancer. These countries are also popular for their low cost of treatment and surgeries, thus being a preferred market for medical tourism.
Countries such as China, Japan, and India are emerging economies with well-developed healthcare infrastructure and facilities. Attributes like high disease burden, significant government reforms, adoption of new technology, and low cost of treatments are paving way for the market growth.
North America dominated the market in 2021 and this trend is expected to continue throughout the forecast period. Increasing Incidence of chronic diseases, an increasing number of surgical procedures performed, well-developed & increasing R&D, and escalating adoption of advanced technology in infusion pumps contributed to the growth of the market in this region.
The U.S. held the largest market share of the North America Intravenous Infusion market due to high disease prevalence, high medical R&D expenditure, and robust healthcare system. The prevalence of diabetes in the U.S. is also quite significant, which can be attributed to their lifestyle and stressed work environment. According to the Centre for Disease Control, 34.2 million population in the U.S. were diagnosed with diabetes in 2018 and the number is expected to elevate in the future.
Some of the prominent players in the Infusion Pump Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Infusion Pump market
By Product
By Application
By End User
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Benefits for Stakeholders
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers